Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7H3-IRDye800CW for Osteosarcoma Resection
NCT06778603Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in osteosarcoma (OS), sponsored by Peking University People's Hospital. Primary endpoint: Safety at 21 days. Started Jan 2024; status: recruiting.
02
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06778603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778603.